- Home
- MLCO vs AKRO Comparison
MLCO vs AKRO Comparison
Compare MLCO & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLCO
- AKRO
- Stock Information
- Founded
- MLCO 2004
- AKRO 2017
- Country
- MLCO Hong Kong
- AKRO United States
- Employees
- MLCO N/A
- AKRO N/A
- Industry
- MLCO Hotels/Resorts
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- MLCO Consumer Discretionary
- AKRO Health Care
- Exchange
- MLCO Nasdaq
- AKRO Nasdaq
- Market Cap
- MLCO 2.9B
- AKRO 2.4B
- IPO Year
- MLCO 2006
- AKRO 2019
- Fundamental
- Price
- MLCO $6.12
- AKRO $28.09
- Analyst Decision
- MLCO Strong Buy
- AKRO Strong Buy
- Analyst Count
- MLCO 6
- AKRO 7
- Target Price
- MLCO $9.85
- AKRO $43.20
- AVG Volume (30 Days)
- MLCO 2.9M
- AKRO 617.2K
- Earning Date
- MLCO 11-05-2024
- AKRO 11-08-2024
- Dividend Yield
- MLCO N/A
- AKRO N/A
- EPS Growth
- MLCO N/A
- AKRO N/A
- EPS
- MLCO N/A
- AKRO N/A
- Revenue
- MLCO $4,540,808,000.00
- AKRO N/A
- Revenue This Year
- MLCO $24.63
- AKRO N/A
- Revenue Next Year
- MLCO $5.76
- AKRO N/A
- P/E Ratio
- MLCO N/A
- AKRO N/A
- Revenue Growth
- MLCO 50.42
- AKRO N/A
- 52 Week Low
- MLCO $4.78
- AKRO $14.41
- 52 Week High
- MLCO $9.56
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- MLCO 35.46
- AKRO 38.58
- Support Level
- MLCO $6.13
- AKRO $31.12
- Resistance Level
- MLCO $6.33
- AKRO $35.11
- Average True Range (ATR)
- MLCO 0.27
- AKRO 1.99
- MACD
- MLCO -0.09
- AKRO -0.53
- Stochastic Oscillator
- MLCO 6.40
- AKRO 11.68
About MLCO Melco Resorts & Entertainment Limited
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao with the rest largely from the Philippines as of 2019.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.